ABCG2与空泡型ATP酶在非小细胞肺癌中的表达及其相关性

目的分析ABCG2和空泡型ATP酶（V—ATPase）在非小细胞肺癌（NSCLC）病理分类、TNM分期、病理分级中表达的差异性以及相关性。方法对92例NSCLC组织样本采用免疫组织化学EnVision法检测ABCG2和V—ATPase的表达。结果ABCG2、V—ATPase在腺癌和鳞癌中有表达，差异有统计学意义（P=0．003、P=0．000）。ABCG2在腺癌TNM分期中的表达差异有统计学意义（P=0．004），在鳞癌TNM分期中差异无统计学意义；在腺癌和鳞癌病理分级的表达差异有统计学意义（P=0．028、P=0．000）。V—ATPase在腺癌TNM分期、鳞癌病理分级间的表达差异有统计学意义（P=0．026、P=0．002），在鳞癌的TNM分期、腺癌病理分级组间的表达差异无统计学意义。在总体样本及腺癌、鳞癌中ABCG2和V—ATPase的表达有相关性。结论V—ATPase可能与ABCG2共同参与NSCLC的多药耐药机制。

Expression and correlation of ABCG2 and V-ATPase in NSCLC

Objective To investigate the expressions of ABCG2 and V-ATPase in NSCLC and their expression rates in pathological classification, TNM stages and pathological grades and the expression correlation between ABCG2 and V-ATPase. Methods Expressions of ABCG2 and V-ATPase were accessed with EnVinsion immunohistochemistry in tumor samples from 92 NSCLC patients. The corresponding data was analyzed statistically. Results Expressions of ABCG2 and V -ATPase were found both in the lung adenocarcinoma and lung squamous cell cancer, and the difference between these two kinds of tumors was significant (P =0.003,0.000). ABCG2 expression was significantly different among TNM stages of lung adenocarcinoma (P=0.004) as well as among pathological grades of lung adenocarcinoma (P =0.028) and squamous cell carcinoma (P =0.000), while no significant difference was found among TNM stages of squamous cell lung carcinoma. The level of V-ATPase expression was associated with TNM stages of lung adenocarcinoma (P =0.026) and pathological grades of lung squamous cell carcinoma (P =0.002), however, among TNM stages of lung squamous cell carcinoma and pathological grades of lung adenocarcinoma, the difference was not significant. Additionally, the significant correlation was found between expression of ABCG2 and V-ATPase in all samples, adenocarcinoma and squamous cell carcinoma (P<0.001). Conclusion The significant correlation is found between expression of ABCG2 and V-ATPase, which indicate that they may co-work to participate in the mechanism of anticancer drug resistance.